Top Ten most popular articles on Pharmafile.com this week
January 19, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alzheimer's, Boehringer, CAR T, CAR-T, Celgene, Kymriah, Merck KGaA, Novartis, Philippines, Sanofi, gilotrif, juno therapeutics, nestle, top ten
It’s Friday, so it’s time to bring you another run-down of the top ten most popular articles with Pharmafile.com’s readers …
Novartis enters biosimilar agreement with Biocon
January 19, 2018Medical Communications, Sales and Marketing Biocon, Novartis, Sandoz, biosimilars, biotech, drugs, pharma, pharmaceutical
Novartis’ Sandoz unit had already staked a claim to being one of the leaders in the developing biosimilar market and …
Pfizer’s Xalkori sees rejection at the hands of NICE in lung cancer
January 19, 2018Medical Communications, Sales and Marketing Cancer, NCIE, NSCLC, Pfizer, UK, Xalkori, lung cancer, pharma
UK regulator NICE has announced its decision not to recommend Pfizer’s Xalkori (crizotinib) for use on the NHS in the …
Gilead aims to claim edge with Pfizer CAR-T combo
January 18, 2018Medical Communications, Research and Development Gilead, Kite, Yescarta, biotech, drugs, pharma, pharmaceutical
Although those in pharma often dislike any references to drugs competing with each other for market as in a ‘race’, …
AstraZeneca expands drug discovery collaboration with X-Chem
January 18, 2018Research and Development, Sales and Marketing AstraZeneca, X-Chem, pharma
AstraZeneca and X-Chem are to expand their existing drug discovery collaboration, it has emerged. The partnership marks the third agreement …
Riding the wave: The FDA and real world evidence
January 18, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing biotech, drugs, pharma, pharmaceutical, real world evidence
Following on from this week’s earlier piece on real world evidence, Jacqueline Corrigan-Curay, Director of CDER’s Office of Medical Policy at the FDA, …
NICE meets Janssen halfway over Darzalex
January 18, 2018Medical Communications, Sales and Marketing J&J, JJ, Janssen, biotech, darzalex, drugs, pharma, pharmaceutical
NICE rejected Janssen’s Darzalex (Daratumumab) back in March last year, concluding that it wasn’t able to accurately determine the efficacy …
Evidence mounts yet again against efficacy of common morning sickness pill
January 18, 2018Research and Development Diclegis, morning sickness, pharma
Evidence is mounting against the efficacy of the common morning sickness pill pyridoxine-doxylamine (Diclegis, Diclectin), as new study data reveals …
Research calls for BRCA testing in all women
January 18, 2018Medical Communications, Research and Development BRCA, biotech, drugs, pharma, pharmaceutical
For women, possessing a mutated BRCA1 or BRCA2 gene significantly increases the chances of developing breast or ovarian cancer; at …
Ipsen ends P3 trial on liver cancer early due to strong data
January 18, 2018Research and Development Cabometyx, Exelixis, biotech, drugs, ipsen, pharma, pharmaceutical
Ipsen and Exelixis, partners in developing Cabometyx (cabozantinib), have revealed that they have cut short a Phase 3 trial into …
Novartis’ CAR T therapy Kymriah scores accelerated approval in both Europe and US
January 17, 2018Research and Development, Sales and Marketing CAR T, CAR-T, EMA, Europe, FDA, Kymriah, Novartis, US, pharma
Following up last year’s ground-breaking news that CAR T therapy Kymriah had become the first such treatment to be approved …
Fully biodegradable sensor offers safer way to monitor lung and brain conditions
January 17, 2018Research and Development biodegradable sensor, pharma, university of connecticut
Engineers at the University of Connecticut have developed a biodegradable pressure sensor which is designed to, once ingested, aid in …
Celgene rumoured to be revving up for Juno buyout
January 17, 2018Research and Development, Sales and Marketing CAR-T, Celgene, Juno, biotech, drugs, pharma, pharmaceutical
Celgene has already started off the year with a bang, announcing a deal with Impact Biomedicines worth a potential $7 …
Digital solutions from Veeva’s European Commercial & Medical Summit
January 17, 2018Medical Communications, Research and Development biotech, drugs, pharma, pharmaceutical, veeva
When Peter Gassner, CEO and founder of Veeva, provided the keynote speech at the company’s European Commercial & Medical Summit, …
MSD’s interim Keytruda combo data spooks Roche and BMS
January 16, 2018Research and Development MSD, Merck, biotech, drugs, keytruda, pharma, pharmaceutical
When PD-1/L1 treatments first came on the market, there was a race to snaffle as many indications as possible for …
GSK Consumer Healthcare announces new Asia Pacific Regional Head
January 16, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing GSK, GlaxoSmithKline
GlaxoSmithKline’s Consumer Healthcare business has revealed that Filippo Lanzi is to take over as Regional Head of Asia Pacific, overseeing …
Hikma bring in new CSO
January 16, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Hikma, biotech, drugs, pharma, pharmaceutical
Hikma Pharmaceuticals has announced that Surendera Tyagi is being brought in to join the company as Group Chief Scientific Officer …
Boehringer’s Gilotrif approved in US for lung cancer with non-resistant EGFRs
January 16, 2018Manufacturing and Production, Sales and Marketing Boehringer Ingelheim, Cancer, FDA, Giltrif, NSCLC, lung cancer
Boehringer Ingelheim is celebrating the FDA’s decision to expand the indication of its lung cancer drug Gilotrif (afatinib) to include …
Mundipharma signs Chinese licensing and distribution agreement with Grünenthal
January 16, 2018Manufacturing and Production China, Grunenthal, Mundipharma, Tramal, pharma
US-based firm Mundipharma is set to take over commercialisation and distribution duties for the analgesic Tramal (tramadol) in China on …
Novartis debuts new data showing Cosentyx’s superiority over Janssen’s Stelara in psoriasis
January 16, 2018Manufacturing and Production, Research and Development Cosentyx, Janssen, Novartis, Stelara, pharma
Novartis has lifted the curtain on new data comparing the efficacy of Cosentyx (secukinumab) to Janssen’s Stelara (ustekinumab) in achieving …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
